vProtect luminal shield stent system wins EU approval: The European Union granted approval to Prescient Medical of Doylestown, Pa., to market its new catheter system for treatment of coronary lesions in patients with symptomatic ischemic heart disease.
Boston Scientific Corp. spent the past two days touting a trio of studies of its defibrillator and stent products, which delivered generally positive results for the Natick, Mass.-based devices giant.
But the results didn’t translate into a stock price boost; after briefly flirting with its yearlong high, BSX stock fell back to earth and was trading at $11.00 as of about 12:15 p.m. Sept. 2.
Judge Susan Robinson of the U.S. District Court for Delaware denied Wyeth’s motion to disqualify Howrey LLP as the Natick, Mass.-based device maker’s counsel, despite Howrey’s representation of Wyeth in a separate, unrelated case in Europe.
Dr. Bruce Saffran, fresh from a $500 million court victory and a private settlement with Boston Scientific over a drug-eluting stent patent, is suing Abbott Laboratories (PDF) for violating the same patent with its Xience V stent.
Saffran, a New Jersey radiologist, won the half-billion-dollar verdict against the Natick, Mass.-based devices giant and later settled for an undisclosed amount (although BoSci later posted a $50 million charge on the deal).
Turn your post-op recovery into a fashion statement: With designer Olivier Trillon’s concepts, you can choose between an Yves Saint Laurent or Chanel IV bag for your post-op morphine drip.
The device, which competes with Boston Scientific‘s Taxus product, uses a different drug, everolimus, than the paclitaxel-eluting Taxus. The drugs are designed to inhibit the re-growth of vascular tissue around the mesh-like stent.
A pair of studies published in Cardiology Today delivered positive results for Boston Scientific Corp.‘s Taxus and Taxus Express drug-eluting stents.
The first study compared the Taxus paclitaxel-eluting stent with Johnson & Johnson subsidiary Cordis Corp.’s Cypher sirolimus-eluting stent in a total of 6,035 patients. It indicated that, a year after implantation with either device, patients showed “similar rates of clinically important restenosis and ischemic complications.”
Boston Scientific Corp. got a boost from Leerink Swann analyst Rick Wise, who upgraded his rating for the Natick, Mass.-based medical devices giant to “outperform.”